Compare Neurocrine Biosciences Inc (NBIX) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Tesla, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Tesla, Inc. trades at $379.29 (market cap $1.39T). The key difference: Tesla, Inc. is far larger — about 79.9× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| NBIX | TSLA | |
|---|---|---|
Market Cap | $17.40B | $1.39T |
Sector | Health | Consumer Cyclical |
52-Week High | $180.55 | $489.88 |
52-Week Low | $123.10 | $302.63 |
Enterprise Value | $16.49B | $1.36T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Tesla (TSLA) trades at $378.88, down 0.51% on the day, as the stock faces technical bearish signals despite recent earnings beats. The company shows mixed fundamentals with revenue declining to $94.83B in 2025 and net income margin compressing to 3.95%, while valuation multiples remain elevated with a P/E of 339.06. Recent news highlights Tesla's strategic pivot toward robotics, AI, and energy growth amid a slowing auto business, with regulatory approval for driver-assistance software in Europe providing a potential catalyst.
Tesla's investment case balances high-growth potential in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $409.26 suggests modest upside, but investors face headwinds from competitive pressures and margin compression. The stock's trajectory will likely hinge on successful commercialization of new technologies and improved automotive profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
